Excessive collagen deposition plays a critical role in the development of fibrosis, and early or active fibrosis may be more susceptible to therapeutic intervention than later stages of scarring. However, at present there is no simple method for assessing the collagen-synthesizing and secreting activity of fibroblasts in human tissues. Type I procollagen carboxyterminal domains are proteolytically removed during collagen secretion. Thus, antibodies to these domains should stain fibroblasts synthesizing type I collagen but not extracellular collagen fibrils which could mask the signal from the cells. We developed and characterized a monoclonal antibody (Anti-pC) specific for the carboxyterminal propeptide of type I procollagen.
Introduction
The fibrotic lung diseases are a heterogeneous group ofdisorders reflecting a common pathophysiologic response of the lung to injury. Whereas in many cases the etiology is clear, cases are frequently of unknown cause, thus creating a significant therapeutic dilemma. Although the pathophysiologic mechanisms remain unclear, progressive connective tissue deposition characterizes fibrotic lung disorders (1) . Histopathological and clinical findings currently guide therapy (2) but there is a clear need for more objective methods to assess disease activity. Determining collagen content oflung biopsies is not a reliable guide to disease activity. In addition to the obvious methodological difficulties, lung collagen may accumulate slowly or explosively, or even exist in excessive quantities as a result of prior disease activity (1, 3, 4) . Furthermore, chemically detectable increases in collagen content may occurr relatively late and thus may not be detectable as a result offocal fibroproliferative reactions. On the other hand, detecting the presence of cells actively secreting collagen in the lung would suggest active connective tissue deposition, i.e., fibrosis. Accordingly, some measure of the numbers and collagensecreting activities of fibroblasts in fibrotic lung could be useful to guide therapy. However, no simple tool to assess the collagensecreting activity of lung fibroblasts in biopsy specimens has emerged to date.
Because type I collagen propeptides are rapidly removed by proteolysis after collagen secretion (5) , antibodies to these peptides might detect cells actively synthesizing collagen by yielding specific intracellular staining without the problems of background staining of preexisting extracellular collagen. Such antibodies might provide results similar to in situ hybridization of collagen mRNA with a cDNA. To test this hypothesis, we developed and characterized a monoclonal antibody to the carboxy terminal domain of human type I procollagen (Anti-pC)' and validated its use in a model system of collagen synthesis, embryonic and adult chicken tendon. In the chicken model, Anti-pC yielded selective intracellular staining offibroblastic cells in embryonic tendon fibroblasts actively synthesizing type I procollagen (6). Adult tendons, where collagen synthesis was minimal, were not stained. However, after laceration and repair, abundant fibroblasts staining for intracellular procollagen appeared at the wound site. We then used Anti-pC to stain normal and fibrotic human lung. Healthy adult human lung did not stain with Anti-pC, whereas fibrotic lung from patients with clinically active pulmonary fibrosis contained abundant staining fibroblasts. These results suggest that Anti-pC selectively detects fibroblasts synthesizing type I procollagen and therefore represents a useful tool for the study of fibroproliferative disorders and wound healing in general. 2 (9) . In some experiments, fibronectin was removed from labeled medium by gelatin-Sepharose absorption before immunoprecipitation to prevent its nonspecific precipitation.
Immunological reagents. Polyclonal rabbit anti-human plasma fibronectin and preimmune rabbit IgG were purified as described (1 1 Mapping ofthe Anti-pC binding domain using procollagen digestion products. Procollagen was subjected to digestion with pepsin, skin collagenase, and bacterial collagenase according to published methods (9, (13) (14) (15) . Crystalline pepsin (Sigma P 6887) and highly purified bacterial collagenase (type VII; see reference 9) were purchased from Sigma Chemical Co., St. Louis, MO.
Immunohistochemistry. Double label immunofluorescence staining of unpermeabilized fibroblasts for fibronectin and procollagen was performed as described (16) using rhodamine isothiocyanate-conjugated, affinity-purified rabbit anti-human plasma fibronectin IgG and AntipC, followed by fluorescein isothiocyanate-conjugated mouse-specific goat anti-mouse IgG. Control Fig. 3 ). Peak C contains type III procollagen, which was not immunoprecipitated with Anti-pC (not shown). (b) deteriorating pulmonary function tests over the previous 3-6 mo; (c) increasing roentgenographic abnormalities on serial chest x-ray; (d) acute respiratory failure with no previous history of respiratory disease and a fatal outcome. Patients were judged to have quiescent disease when there was no change in categories 1-3 for a minimum of 6 mo after the biopsy.
Animal models. Anti-pC recognized both chicken and calfprocollagen type I, so we used the chicken flexor tendon as a model tissue synthesizing type I collagen to examine the relationship between staining of fibroblasts with Anti-pC and collagen synthesis. Immunohistochemical studies were performed on 16-d chick embryos and adult white male leghorn chickens. Intact embryos and excised adult tendons were fixed in acetic aid-ethanol fixative and embedded, and the paraffin sections processed identically to those of lung specimens. For studies of tendon healing, we used the animal model of Birdsell et al. (18) , who demonstrated more than 10-fold increases in collagen synthesis at the wound site of lacerated and repaired chicken flexor digitorum profundus tendons, and much smaller increases in collagen synthesis in the same tendon distal to the wound site (18) . The tendon was exposed, lacerated, sutured, and replaced in the tendon sheath. After 21 d, the tendon was removed, fixed, and processed for immunohistochemistry.
Results

Characterization ofprocollagen I antibody
Anti-pC is an IgG that specifically immunoprecipitated procollagen type I from fibroblast medium (Fig. 1, lanes I and 2) . To map the binding site ofAnti-pC, we used several selective enzyme digestions of procollagen to release specific domains and isolated physiologically processed collagen precursors from IMR-90 medium. Pepsin treatment of culture medium converts type I procollagen to collagen by removing the amino and carboxyterminal propeptides as well as telopeptide extensions from procollagen. Anti-pC did not immunoprecipitate any polypeptides from pepsin-treated fibroblast culture medium. Therefore, Anti-pC bound to either the propeptide or telopeptide regions of type I procollagen (Fig. 1, lanes 3 and 4) . Digestion of type I procollagen with purified bacterial collagenase selectively degraded triple helical domains of procollagen, thus releasing intact the carboxyterminal telopeptide and disulfide crosslinked propeptide domains (14, 15) . Afterdigestion of labeled fibroblast medium with highly purified bacterial collagenase, several noncollagenous polypeptides remained (Fig. 1,  lane 5) . Immunoprecipitation of this mixture yielded two polypeptides with apparent reduced molecular masses of 35 and 32 kD (Fig. 1, lane 6) . Unreduced, these polypeptides migrated with apparent molecular mass of 110 kD (Fig. 1, lane 7) . The apparent molecular mass ofthis disulfide crosslinked polypeptide is similar to previous estimates of the molecular mass of the trimeric carboxyterminal propeptides of type I procollagen (14, 15) .
Vertebrate collagenase (purified human skin fibroblast collagenase, generously provided by Dr. Howard F. Welgus, Dermatology Division, The Jewish Hospital of St. Louis, St. Louis, MO) cleaves type I procollagen at a site in the collagenous domain approximately three quarters ofthe length from the amino terminus, releasing a trimeric disulfide crosslinked fiagment comprised ofthe carboxyterminal one quarter ofthe collagenous domains and the intact carboxyterminal propeptides (13) . Fibroblast collagenase released from labeled fibroblast medium two major pairs of polypeptides (Mr = 120, 150, 63, and 56 kD reduced) representing the aminoterminal and carboxyterminal mammalian collagenase cleavage products of type I procollagen, respectively (Fig. 1, lane 8) . The smaller of these pairs representing the carboxyterminal vertebrate collagenase cleavage product was selectively immunoprecipitated with Anti-pC (Fig.  1, lane 9) . Thus, both bacterial and vertebrate collagenase digestion results were compatible with Anti-pC binding to a site either in the carboxyterminal telopeptide or propeptide domain oftype I procollagen.
To further evaluate the Anti-pC epitope, we isolated intact and partially processed procollagen using DEAE-cellulose chromatography ( Fig. 2) (7) . Anti-pC specifically precipitated pCand intact type I procollagen but not pN-or fully processed collagen (Fig. 3) . Because processing ofprocollagen by cells and tissues to pN-collagen results in cleavage between the carboxyterminal telopeptide and propeptide domains, these data suggest that Anti-pC binds to the carboxyterminal domain of type I procollagen (5).
Immunostaining results Relationship ofAnti-pC staining to the collagen-synthesizing activity ofembryonic and adult tissues. As expected from previous results (16, 19) , Anti-pC stained cultured IMR-90 matrix identically to anti-fibronectin antibodies (not shown). This staining, as well as the staining offibrotic lung, was completely prevented by formalin fixation. Anti-pC also stained cells in embryonic chick tissues known to be actively synthesizing type I collagen, including osteoblasts and tendon fibroblasts (6) (Fig. 4 A) . To explore the relationship between onset of collagen synthesis induced by wounding and the acquisition of fibroblast staining by Anti-pC, we stained normal and wounded adult chicken tendon. As shown in Fig. 4 B, unwounded chicken tendon did not stain with Anti-pC. Three weeks after wounding, when collagen synthesis was shown to be greatly increased (18) , the wound site contained abundant fibroblasts with heavy intracellular staining (Fig. 4 C) , whereas the same tendon exhibited no staining 1 cm distal to the wound site (not shown).
Staining ofnormal andfibrotic lung with Anti-pC. Although normal lung (Fig. 5) control experiments with antibodies to fibronectin, laminin, and type IV collagen (not shown) gave the expected localization to basal lamina (20) . Thus, Anti-pC stained cultured lung fibroblast matrix, previously demonstrated to contain procollagen type I (16), as well as embryonic and healing adult tendons but not normal adult tendon or lung. Lung biopsies from six patients with pulmonary interstitial fibrosis, either idiopathic or related to other diseases (Table I) , were stained for type I procollagen with Anti-pC. The spectrum of staining patterns observed is illustrated in Fig. 6 , which contains low and high power views of results obtained in three different patients. Fig. 6, A and B is a biopsy obtained from patient C.S. who had rheumatoid disease and accelerated fibrosis with a fatal outcome (21) . Anti-pC stained myriad fibroblastic cells in the greatly thickened interstitium. A higher magnification image ofthis specimen shown in Fig. 6 B displays the fibroblastic morphology of the stained cells as well as the total absence of extracellular staining. Patient D.G., who had a more slowly progressive course, showed clusters of positively stained cells (Fig.  6 C) , which at higher power were fibroblastic in appearance (Fig. 6 D) . However, Anti-pC was not a general stain for all lung fibroblasts, as results in clinically quiescent disease demonstrated. For example, patient E.M. had idiopathic pulmonary fibrosis for many years. The disease progressed very slowly and culminated in respiratory failure and death. The lung, massively fibrotic and honeycombed, contained abundant fibroblasts but no fibroblastic cells stained with Anti-pC (Fig. 6, D and E) .
Discussion
Immunoprecipitation of the domains of procollagen type I, obtained by selective enzymatic digestion, and of physiologically processed forms of type I procollagen are compatible with AntipC binding to the carboxyterminal domain of type I procollagen. Anti-pC did not immunoprecipitate type III procollagen from the same cultures. Although we have not performed competitive binding assays, it is unlikely that Anti-pC will crossreact with other types of procollagen. Even polyclonal antisera to the carboxyterminal domain of type I procollagen are highly selective for type I procollagen ( 15) .
Anti-pC has the properties of an antibody specifically detecting type I collagen-synthesizing cells. Embryonic chick tissues actively synthesizing type I procollagen such as osteoblasts and tendon fibroblasts exhibit heavy intracellular staining, whereas adult tendon fibroblasts do not stain. Fibroblasts at the wound site of lacerated adult chicken tendons developed marked intracellular staining, thus demonstrating that Anti-pC stains wound fibroblasts synthesizing type I collagen. Interestingly, Anti-pC stained lung fibroblasts in biopsies from patients with clinically active pulmonary fibrosis, but not normal lung tissue. Biopsies from a larger series of patients must be studied to correlate antibody staining with disease activity. However, we can conclude that cells containing procollagen type I in vivo can be easily identified with Anti-pC. Moreover, in active pulmonary fibrosis, the number of fibroblasts staining for procollagen and their average intracellular collagen content (and almost certainly their synthetic activity) is increased. Thus, it appears clear from this and related studies that unknown factors in pulmonary fibrosis stimulate both increased numbers offibroblasts and a more active fibroblast synthetic phenotype (1, 3, 21, 22) . Lung fibroblasts staining with Anti-pC could contain more procollagen than fibroblasts from quiescent lung simply because procollagen secretion is somehow impeded, as in the case of ascorbate deprivation (23) . This is unlikely, as dermal fibroblasts maintained in vitro under ascorbate-replete conditions, where procollagen secretion should be optimal, have intracellular pools of type I procollagen readily detectable by similar immunohistological techniques (19). Moreover, we have observed similar intracellular staining of IMR-90 cultured with ascorbate using Anti-pC.
There are no reported studies on the immunohistochemical localization of type I procollagen in human lung fibrosis, and few studies employing antibodies specific for procollagen in any human tissue. In embryonic and adult skin, immunoferritin staining shows persistence of types I and III collagen aminoterminal propeptides in collagen fibrils, whereas the carboxyterminal propeptide is not associated with collagen fibrils (24, 25) . Antibodies to the aminoterminal propeptide of type III procollagen stained extracellular reticulin and collagen in liver (26) . Notably, hepatocytes in cirrhotic liver exhibited intracellular staining similar to that seen in this study, suggesting heightened synthesis of type III collagen by hepatocytes (26) . In fibrotic human lung, immunohistochemical detection of types I and III collagen has revealed apparent increases in type III that correlate somewhat with disease activity (4) , but no studies ofprocollagen staining were performed.
Anti-pC may prove useful in the noninvasive assessment of disease activity. The absence of extracellular staining for the carboxyterminal domain of type I procollagen in chicken embryos and adult human fibrotic lung suggests that this domain is rapidly cleaved and removed in vivo, as previously suggested (5) . Hence, quantitative immunoassays of serum or bronchial lavage fluid for the carboxyterminal propeptide may be useful in assessing collagen synthesis and deposition. Several investigators have used quantitative assays for type III collagen precursor extension peptides ("propeptides") to study lung and liver fibrosis. Consistent with histochemical findings cited above, the amino terminal propeptide of collagen type III is elevated in serum of patients with alcoholic liver disease and hepatic fibrosis where increased concentrations may correlate with disease activity assessed histologically or clinically (27, 28). Elevated bronchoalveolar lavage fluid and serum levels oftype III procollagen N-terminal peptide have also been found in patients with idiodid not appear to be due to peroxidase reaction product. The smaller stained circular profiles are fibroblasts cut in cross section, with reaction product surrounding the nucleus. Only some cells have nuclei within the plane of the section, so the rest appear solidly stained. Some cells in the figure appear to have two holes. Whether pathic fibrotic lung disease and sarcoidosis (29, 30) . These peptides likely appear in plasma and bronchoalveolar lavage fluid because they are removed rapidly after collagen secretion. Because collagen type I is the major collagen synthesized in lung (31) , levels of carboxyterminal propeptide in biological fluids obtained from patients with pulmonary fibrosis warrant evaluation.
Finally, the carboxyterminal antigen present in fetal lung fibroblast pericellular matrix deposited in tissue culture is not present in vivo, where the antigen was only detected intracellularly. This result indicates that the posttranslational proteolytic processing of procollagen is much more complete in lung and other organs than in the cultured IMR-90 we studied or in adult dermal fibroblasts (19, 32). Whereas fibroblast culture is a convenient and therefore frequently used model, the fidelity with which this model reflects the complex events of collagen synthesis, processing, and deposition in vivo is uncertain.
